Selective cyclooxygenase-2 inhibitors and XXXX .

@entity5 @entity957 @entity2 @entity1149 @entity2918 @entity1442 @entity2247 @entity204 @entity2220
@entity2 is the leading cause of @entity204 from @entity5 in most developed nations. The most common type of @entity2 is of non-small cell histology, representing approximately 80% of the total. Despite aggressive treatments in early stages and improvement of polychemotherapy outcomes in @entity1442 , the five years survival rate for @entity2 remains under 15%. Fortunately, our improved knowledge of @entity5 biology and mechanisms of oncogenesis suggests several new potential targets for clinical research in @entity5 therapy. A substantial body of evidence indicates that @entity2247 and @entity2918 (PGs) play an important role in tumorigenesis. Mechanisms involved in @entity2247 participation in tumorigenesis and @entity5 growth include xenobiotic metabolism, angiogenesis stimulation, inhibition of immune surveillance and inhibition of apoptosis. @entity2247 is frequently overexpressed in bronchial premalignancy, @entity2220 and @entity957 and @entity2247 overexpression is a marker of poor prognosis in surgically resected stage I @entity1149 . Treatment with @entity2247 inhibitors reduces the growth of NSCLC cells in vitro and in xenograft studies. Recent studies have defined some of the mechanisms involved in @entity2247 participation in NSCLC development and diffusion. These evidences support the hypothesis that selective @entity2247 inhibitors (coxibs) may prove beneficial in the prevention and treatment of NSCLC.
